Arevipharma

Arevipharma is a privately held, medium-sized CDMO and API manufacturer based in Munich, Germany, with operational facilities in Radebeul. Founded in 2018 but rooted in a 150-year legacy of chemical synthesis, the company provides end-to-end services from process development to commercial-scale manufacturing, emphasizing flexibility, quality, and regulatory expertise. It holds over 150 global authorizations for its substances and serves small, medium, and large pharmaceutical customers worldwide, with a noted specialization in controlled substances for oncology and immunology.

Integrated CDMO platform specializing in synthetic organic chemistry, process development, and cGMP manufacturing of APIs, with particular expertise in handling narcotics and potent compounds. Capabilities span from gram-scale development to multi-tonne commercial production, supported by in-house analytical, regulatory, and logistics services.

Arevipharma competes in the global CDMO market against large, publicly traded players like Lonza, Catalent, and Siegfried, as well as numerous specialized and regional manufacturers. Its key competitive differentiators are its deep historical expertise in chemical synthesis, specialization in narcotics, fully integrated German site, and the flexibility of a privately held medium-sized enterprise. It must continually demonstrate that these advantages outweigh potential cost disadvantages compared to some competitors.